Loading…
Advances in the treatment of Chagas disease: Promising new drugs, plants and targets
Chagas disease, caused by Trypanosoma cruzi, is treated with only two drugs; benznidazole and nifurtimox. These drugs have some disadvantages, including their efficacy only in the acute or early infection phases, adverse effects during their use, and the resistance that the parasite has developed to...
Saved in:
Published in: | Biomedicine & pharmacotherapy 2021-10, Vol.142, p.112020-112020, Article 112020 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c408t-8ee9b5c65b8fd572ca1205d080f7995109b3c7385cea01d085500834e5cea0193 |
---|---|
cites | cdi_FETCH-LOGICAL-c408t-8ee9b5c65b8fd572ca1205d080f7995109b3c7385cea01d085500834e5cea0193 |
container_end_page | 112020 |
container_issue | |
container_start_page | 112020 |
container_title | Biomedicine & pharmacotherapy |
container_volume | 142 |
creator | García-Huertas, Paola Cardona-Castro, Nora |
description | Chagas disease, caused by Trypanosoma cruzi, is treated with only two drugs; benznidazole and nifurtimox. These drugs have some disadvantages, including their efficacy only in the acute or early infection phases, adverse effects during their use, and the resistance that the parasite has developed to their activity. Therefore, it is necessary to identify new, safe and effective therapeutic alternatives to treat Chagas disease, though governments and the pharmaceutical industry have shown a lack of interest in contributing to this solution. Institutions and research groups on the other hand have worked on some strategies that can help to address the problem. Some of these include the modification of conventional drug dosages, drug repurposing, and combined therapy. Plants and derived compounds with antiparasitic effects have also been studied, taking advantage of traditional medicinal knowledge. Others have studied the parasite to identify essential genes that can be used as therapeutic targets to design new, targeted drugs. Some of these studies have generated promising results, but few reach clinical phase studies. Institutions and research groups should be encouraged to unify efforts and cover all aspects of drug development according to resources and knowledge availability. In the end, this exchange of knowledge would lead to the development of new therapeutic alternatives to treat Chagas disease and benefit the populations it affects.
[Display omitted]
•Drug repurposing and medicinal plants are a potential source of therapeutic options.•Biological processes of T. cruzi are a source of therapeutic targets for drug design.•Despite efforts, the treatment of Chagas disease continues without an effective solution.•Institutions and research groups should be encouraged to cover all drug development. |
doi_str_mv | 10.1016/j.biopha.2021.112020 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2561917292</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332221008039</els_id><sourcerecordid>2561917292</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-8ee9b5c65b8fd572ca1205d080f7995109b3c7385cea01d085500834e5cea0193</originalsourceid><addsrcrecordid>eNp9kEtLAzEUhYMoWh__QCRLF069SZqZiQuhFF8g6ELXIZPcaVPamZqkiv_eyKhLVwcO59zHR8gpgzEDVl4ux43vNwsz5sDZmLEssENGTEkoSoBql4ygkqIQgvMDchjjEgBkKep9ciAmQnGoqxF5mbp301mM1Hc0LZCmgCatsUu0b-lsYeYmUucjmohX9Dn0ax99N6cdflAXtvN4QTcr06VITedoMmGOKR6TvdasIp786BF5vb15md0Xj093D7PpY2EnUKeiRlSNtKVs6tbJiluTn5AOamgrpSQD1QhbiVpaNMCyLyVALSY4GEockfNh7ib0b1uMSefrLK7yQdhvo-ayZIpVXPEcnQxRG_oYA7Z6E_zahE_NQH_z1Es98NTfPPXAM9fOfjZsmzW6v9IvwBy4HgKY_3z3GHS0HjNQ5wPapF3v_9_wBR-Jhuc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2561917292</pqid></control><display><type>article</type><title>Advances in the treatment of Chagas disease: Promising new drugs, plants and targets</title><source>ScienceDirect Journals</source><creator>García-Huertas, Paola ; Cardona-Castro, Nora</creator><creatorcontrib>García-Huertas, Paola ; Cardona-Castro, Nora</creatorcontrib><description>Chagas disease, caused by Trypanosoma cruzi, is treated with only two drugs; benznidazole and nifurtimox. These drugs have some disadvantages, including their efficacy only in the acute or early infection phases, adverse effects during their use, and the resistance that the parasite has developed to their activity. Therefore, it is necessary to identify new, safe and effective therapeutic alternatives to treat Chagas disease, though governments and the pharmaceutical industry have shown a lack of interest in contributing to this solution. Institutions and research groups on the other hand have worked on some strategies that can help to address the problem. Some of these include the modification of conventional drug dosages, drug repurposing, and combined therapy. Plants and derived compounds with antiparasitic effects have also been studied, taking advantage of traditional medicinal knowledge. Others have studied the parasite to identify essential genes that can be used as therapeutic targets to design new, targeted drugs. Some of these studies have generated promising results, but few reach clinical phase studies. Institutions and research groups should be encouraged to unify efforts and cover all aspects of drug development according to resources and knowledge availability. In the end, this exchange of knowledge would lead to the development of new therapeutic alternatives to treat Chagas disease and benefit the populations it affects.
[Display omitted]
•Drug repurposing and medicinal plants are a potential source of therapeutic options.•Biological processes of T. cruzi are a source of therapeutic targets for drug design.•Despite efforts, the treatment of Chagas disease continues without an effective solution.•Institutions and research groups should be encouraged to cover all drug development.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2021.112020</identifier><identifier>PMID: 34392087</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Animals ; Chagas disease ; Chagas Disease - drug therapy ; Chagas Disease - parasitology ; Drug Development - methods ; Drug repurposing ; Drug Resistance ; Humans ; Medicine, Traditional - methods ; Molecular Targeted Therapy ; New treatments ; Nifurtimox - therapeutic use ; Nitroimidazoles - therapeutic use ; Plant Preparations - pharmacology ; Promising plants ; Therapeutics target ; Trypanocidal Agents - pharmacology ; Trypanosoma cruzi ; Trypanosoma cruzi - drug effects</subject><ispartof>Biomedicine & pharmacotherapy, 2021-10, Vol.142, p.112020-112020, Article 112020</ispartof><rights>2021</rights><rights>Copyright © 2021. Published by Elsevier Masson SAS.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-8ee9b5c65b8fd572ca1205d080f7995109b3c7385cea01d085500834e5cea0193</citedby><cites>FETCH-LOGICAL-c408t-8ee9b5c65b8fd572ca1205d080f7995109b3c7385cea01d085500834e5cea0193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34392087$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>García-Huertas, Paola</creatorcontrib><creatorcontrib>Cardona-Castro, Nora</creatorcontrib><title>Advances in the treatment of Chagas disease: Promising new drugs, plants and targets</title><title>Biomedicine & pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Chagas disease, caused by Trypanosoma cruzi, is treated with only two drugs; benznidazole and nifurtimox. These drugs have some disadvantages, including their efficacy only in the acute or early infection phases, adverse effects during their use, and the resistance that the parasite has developed to their activity. Therefore, it is necessary to identify new, safe and effective therapeutic alternatives to treat Chagas disease, though governments and the pharmaceutical industry have shown a lack of interest in contributing to this solution. Institutions and research groups on the other hand have worked on some strategies that can help to address the problem. Some of these include the modification of conventional drug dosages, drug repurposing, and combined therapy. Plants and derived compounds with antiparasitic effects have also been studied, taking advantage of traditional medicinal knowledge. Others have studied the parasite to identify essential genes that can be used as therapeutic targets to design new, targeted drugs. Some of these studies have generated promising results, but few reach clinical phase studies. Institutions and research groups should be encouraged to unify efforts and cover all aspects of drug development according to resources and knowledge availability. In the end, this exchange of knowledge would lead to the development of new therapeutic alternatives to treat Chagas disease and benefit the populations it affects.
[Display omitted]
•Drug repurposing and medicinal plants are a potential source of therapeutic options.•Biological processes of T. cruzi are a source of therapeutic targets for drug design.•Despite efforts, the treatment of Chagas disease continues without an effective solution.•Institutions and research groups should be encouraged to cover all drug development.</description><subject>Animals</subject><subject>Chagas disease</subject><subject>Chagas Disease - drug therapy</subject><subject>Chagas Disease - parasitology</subject><subject>Drug Development - methods</subject><subject>Drug repurposing</subject><subject>Drug Resistance</subject><subject>Humans</subject><subject>Medicine, Traditional - methods</subject><subject>Molecular Targeted Therapy</subject><subject>New treatments</subject><subject>Nifurtimox - therapeutic use</subject><subject>Nitroimidazoles - therapeutic use</subject><subject>Plant Preparations - pharmacology</subject><subject>Promising plants</subject><subject>Therapeutics target</subject><subject>Trypanocidal Agents - pharmacology</subject><subject>Trypanosoma cruzi</subject><subject>Trypanosoma cruzi - drug effects</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kEtLAzEUhYMoWh__QCRLF069SZqZiQuhFF8g6ELXIZPcaVPamZqkiv_eyKhLVwcO59zHR8gpgzEDVl4ux43vNwsz5sDZmLEssENGTEkoSoBql4ygkqIQgvMDchjjEgBkKep9ciAmQnGoqxF5mbp301mM1Hc0LZCmgCatsUu0b-lsYeYmUucjmohX9Dn0ax99N6cdflAXtvN4QTcr06VITedoMmGOKR6TvdasIp786BF5vb15md0Xj093D7PpY2EnUKeiRlSNtKVs6tbJiluTn5AOamgrpSQD1QhbiVpaNMCyLyVALSY4GEockfNh7ib0b1uMSefrLK7yQdhvo-ayZIpVXPEcnQxRG_oYA7Z6E_zahE_NQH_z1Es98NTfPPXAM9fOfjZsmzW6v9IvwBy4HgKY_3z3GHS0HjNQ5wPapF3v_9_wBR-Jhuc</recordid><startdate>202110</startdate><enddate>202110</enddate><creator>García-Huertas, Paola</creator><creator>Cardona-Castro, Nora</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202110</creationdate><title>Advances in the treatment of Chagas disease: Promising new drugs, plants and targets</title><author>García-Huertas, Paola ; Cardona-Castro, Nora</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-8ee9b5c65b8fd572ca1205d080f7995109b3c7385cea01d085500834e5cea0193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Chagas disease</topic><topic>Chagas Disease - drug therapy</topic><topic>Chagas Disease - parasitology</topic><topic>Drug Development - methods</topic><topic>Drug repurposing</topic><topic>Drug Resistance</topic><topic>Humans</topic><topic>Medicine, Traditional - methods</topic><topic>Molecular Targeted Therapy</topic><topic>New treatments</topic><topic>Nifurtimox - therapeutic use</topic><topic>Nitroimidazoles - therapeutic use</topic><topic>Plant Preparations - pharmacology</topic><topic>Promising plants</topic><topic>Therapeutics target</topic><topic>Trypanocidal Agents - pharmacology</topic><topic>Trypanosoma cruzi</topic><topic>Trypanosoma cruzi - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>García-Huertas, Paola</creatorcontrib><creatorcontrib>Cardona-Castro, Nora</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine & pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>García-Huertas, Paola</au><au>Cardona-Castro, Nora</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advances in the treatment of Chagas disease: Promising new drugs, plants and targets</atitle><jtitle>Biomedicine & pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2021-10</date><risdate>2021</risdate><volume>142</volume><spage>112020</spage><epage>112020</epage><pages>112020-112020</pages><artnum>112020</artnum><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Chagas disease, caused by Trypanosoma cruzi, is treated with only two drugs; benznidazole and nifurtimox. These drugs have some disadvantages, including their efficacy only in the acute or early infection phases, adverse effects during their use, and the resistance that the parasite has developed to their activity. Therefore, it is necessary to identify new, safe and effective therapeutic alternatives to treat Chagas disease, though governments and the pharmaceutical industry have shown a lack of interest in contributing to this solution. Institutions and research groups on the other hand have worked on some strategies that can help to address the problem. Some of these include the modification of conventional drug dosages, drug repurposing, and combined therapy. Plants and derived compounds with antiparasitic effects have also been studied, taking advantage of traditional medicinal knowledge. Others have studied the parasite to identify essential genes that can be used as therapeutic targets to design new, targeted drugs. Some of these studies have generated promising results, but few reach clinical phase studies. Institutions and research groups should be encouraged to unify efforts and cover all aspects of drug development according to resources and knowledge availability. In the end, this exchange of knowledge would lead to the development of new therapeutic alternatives to treat Chagas disease and benefit the populations it affects.
[Display omitted]
•Drug repurposing and medicinal plants are a potential source of therapeutic options.•Biological processes of T. cruzi are a source of therapeutic targets for drug design.•Despite efforts, the treatment of Chagas disease continues without an effective solution.•Institutions and research groups should be encouraged to cover all drug development.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>34392087</pmid><doi>10.1016/j.biopha.2021.112020</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0753-3322 |
ispartof | Biomedicine & pharmacotherapy, 2021-10, Vol.142, p.112020-112020, Article 112020 |
issn | 0753-3322 1950-6007 |
language | eng |
recordid | cdi_proquest_miscellaneous_2561917292 |
source | ScienceDirect Journals |
subjects | Animals Chagas disease Chagas Disease - drug therapy Chagas Disease - parasitology Drug Development - methods Drug repurposing Drug Resistance Humans Medicine, Traditional - methods Molecular Targeted Therapy New treatments Nifurtimox - therapeutic use Nitroimidazoles - therapeutic use Plant Preparations - pharmacology Promising plants Therapeutics target Trypanocidal Agents - pharmacology Trypanosoma cruzi Trypanosoma cruzi - drug effects |
title | Advances in the treatment of Chagas disease: Promising new drugs, plants and targets |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T07%3A48%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advances%20in%20the%20treatment%20of%20Chagas%20disease:%20Promising%20new%20drugs,%20plants%20and%20targets&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Garc%C3%ADa-Huertas,%20Paola&rft.date=2021-10&rft.volume=142&rft.spage=112020&rft.epage=112020&rft.pages=112020-112020&rft.artnum=112020&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2021.112020&rft_dat=%3Cproquest_cross%3E2561917292%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c408t-8ee9b5c65b8fd572ca1205d080f7995109b3c7385cea01d085500834e5cea0193%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2561917292&rft_id=info:pmid/34392087&rfr_iscdi=true |